TocilizumabV1, Main, Exploration, bibRecord, 000421

Effect on efficacy and safety trial outcomes of also enrolling patients on ongoing glucocorticoid therapy in rheumatoid arthritis clinical trials of tocilizumab or adalimumab or methotrexate monotherapy.

Identifieur interne : 000421 ( Main/Exploration ); précédent : 000420; suivant : 000422

Effect on efficacy and safety trial outcomes of also enrolling patients on ongoing glucocorticoid therapy in rheumatoid arthritis clinical trials of tocilizumab or adalimumab or methotrexate monotherapy.

Auteurs : Mary Safy-Khan [Oman] ; Johannes W G. Jacobs [Pays-Bas] ; Maria J H. De Hair [Pays-Bas] ; Paco M J. Welsing [Pays-Bas] ; Michael D. Edwardes [Canada] ; Xavier M. Teitsma [Suisse] ; Yves Luder ; Jenny Devenport [Suisse] ; Jacob M. Van Laar [Pays-Bas] ; Attila Pethoe-Schramm [Suisse] ; Johannes W J. Bijlsma [Pays-Bas]

Source :

Annals of the rheumatic diseases [ 1468-2060 ] ; 2020.

RBID : pubmed:32033935

Abstract

In rheumatoid arthritis (RA) trials, inclusion of patients on background treatment with glucocorticoids (GCs) might impact efficacy and safety outcomes.

DOI: 10.1136/annrheumdis-2019-216537
PubMed: 32033935

Affiliations:

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Effect on efficacy and safety trial outcomes of also enrolling patients on ongoing glucocorticoid therapy in rheumatoid arthritis clinical trials of tocilizumab or adalimumab or methotrexate monotherapy.</title>
<author><name sortKey="Safy Khan, Mary" sort="Safy Khan, Mary" uniqKey="Safy Khan M" first="Mary" last="Safy-Khan">Mary Safy-Khan</name>
<affiliation wicri:level="3"><nlm:affiliation>Department of Rheumatology and Clinical Immunology, UMC Utrecht, Utrecht, The Netherlands marysafy@hotmail.com.</nlm:affiliation>
<country wicri:rule="url">Oman</country>
<wicri:regionArea>Department of Rheumatology and Clinical Immunology, UMC Utrecht, Utrecht</wicri:regionArea>
<placeName><settlement type="city">Utrecht</settlement>
<region nuts="2" type="province">Utrecht (province)</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Jacobs, Johannes W G" sort="Jacobs, Johannes W G" uniqKey="Jacobs J" first="Johannes W G" last="Jacobs">Johannes W G. Jacobs</name>
<affiliation wicri:level="3"><nlm:affiliation>Department of Rheumatology and Clinical Immunology, UMC Utrecht, Utrecht, The Netherlands.</nlm:affiliation>
<country xml:lang="fr">Pays-Bas</country>
<wicri:regionArea>Department of Rheumatology and Clinical Immunology, UMC Utrecht, Utrecht</wicri:regionArea>
<placeName><settlement type="city">Utrecht</settlement>
<region nuts="2" type="province">Utrecht (province)</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="De Hair, Maria J H" sort="De Hair, Maria J H" uniqKey="De Hair M" first="Maria J H" last="De Hair">Maria J H. De Hair</name>
<affiliation wicri:level="3"><nlm:affiliation>Novartis Pharma BV, Amsterdam, The Netherlands.</nlm:affiliation>
<country xml:lang="fr">Pays-Bas</country>
<wicri:regionArea>Novartis Pharma BV, Amsterdam</wicri:regionArea>
<placeName><settlement type="city">Amsterdam</settlement>
<region nuts="2" type="province">Hollande-Septentrionale</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Welsing, Paco M J" sort="Welsing, Paco M J" uniqKey="Welsing P" first="Paco M J" last="Welsing">Paco M J. Welsing</name>
<affiliation wicri:level="3"><nlm:affiliation>Department of Rheumatology and Clinical Immunology, UMC Utrecht, Utrecht, The Netherlands.</nlm:affiliation>
<country xml:lang="fr">Pays-Bas</country>
<wicri:regionArea>Department of Rheumatology and Clinical Immunology, UMC Utrecht, Utrecht</wicri:regionArea>
<placeName><settlement type="city">Utrecht</settlement>
<region nuts="2" type="province">Utrecht (province)</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Edwardes, Michael D" sort="Edwardes, Michael D" uniqKey="Edwardes M" first="Michael D" last="Edwardes">Michael D. Edwardes</name>
<affiliation wicri:level="1"><nlm:affiliation>Everest Clinical Research Canada, Markham, Ontario, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Everest Clinical Research Canada, Markham, Ontario</wicri:regionArea>
<wicri:noRegion>Ontario</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Teitsma, Xavier M" sort="Teitsma, Xavier M" uniqKey="Teitsma X" first="Xavier M" last="Teitsma">Xavier M. Teitsma</name>
<affiliation wicri:level="1"><nlm:affiliation>F Hoffmann-La Roche AG, Basel, Basel-Stadt, Switzerland.</nlm:affiliation>
<country xml:lang="fr">Suisse</country>
<wicri:regionArea>F Hoffmann-La Roche AG, Basel, Basel-Stadt</wicri:regionArea>
<wicri:noRegion>Basel-Stadt</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Luder, Yves" sort="Luder, Yves" uniqKey="Luder Y" first="Yves" last="Luder">Yves Luder</name>
</author>
<author><name sortKey="Devenport, Jenny" sort="Devenport, Jenny" uniqKey="Devenport J" first="Jenny" last="Devenport">Jenny Devenport</name>
<affiliation wicri:level="1"><nlm:affiliation>F Hoffmann-La Roche AG, Basel, Basel-Stadt, Switzerland.</nlm:affiliation>
<country xml:lang="fr">Suisse</country>
<wicri:regionArea>F Hoffmann-La Roche AG, Basel, Basel-Stadt</wicri:regionArea>
<wicri:noRegion>Basel-Stadt</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Van Laar, Jacob M" sort="Van Laar, Jacob M" uniqKey="Van Laar J" first="Jacob M" last="Van Laar">Jacob M. Van Laar</name>
<affiliation wicri:level="3"><nlm:affiliation>Department of Rheumatology and Clinical Immunology, UMC Utrecht, Utrecht, The Netherlands.</nlm:affiliation>
<country xml:lang="fr">Pays-Bas</country>
<wicri:regionArea>Department of Rheumatology and Clinical Immunology, UMC Utrecht, Utrecht</wicri:regionArea>
<placeName><settlement type="city">Utrecht</settlement>
<region nuts="2" type="province">Utrecht (province)</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Pethoe Schramm, Attila" sort="Pethoe Schramm, Attila" uniqKey="Pethoe Schramm A" first="Attila" last="Pethoe-Schramm">Attila Pethoe-Schramm</name>
<affiliation wicri:level="1"><nlm:affiliation>F Hoffmann-La Roche AG, Basel, Basel-Stadt, Switzerland.</nlm:affiliation>
<country xml:lang="fr">Suisse</country>
<wicri:regionArea>F Hoffmann-La Roche AG, Basel, Basel-Stadt</wicri:regionArea>
<wicri:noRegion>Basel-Stadt</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Bijlsma, Johannes W J" sort="Bijlsma, Johannes W J" uniqKey="Bijlsma J" first="Johannes W J" last="Bijlsma">Johannes W J. Bijlsma</name>
<affiliation wicri:level="3"><nlm:affiliation>Department of Rheumatology and Clinical Immunology, UMC Utrecht, Utrecht, The Netherlands.</nlm:affiliation>
<country xml:lang="fr">Pays-Bas</country>
<wicri:regionArea>Department of Rheumatology and Clinical Immunology, UMC Utrecht, Utrecht</wicri:regionArea>
<placeName><settlement type="city">Utrecht</settlement>
<region nuts="2" type="province">Utrecht (province)</region>
</placeName>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2020">2020</date>
<idno type="RBID">pubmed:32033935</idno>
<idno type="pmid">32033935</idno>
<idno type="doi">10.1136/annrheumdis-2019-216537</idno>
<idno type="wicri:Area/PubMed/Corpus">000152</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000152</idno>
<idno type="wicri:Area/PubMed/Curation">000152</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000152</idno>
<idno type="wicri:Area/PubMed/Checkpoint">000176</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000176</idno>
<idno type="wicri:Area/Ncbi/Merge">002881</idno>
<idno type="wicri:Area/Ncbi/Curation">002881</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">002881</idno>
<idno type="wicri:Area/Main/Merge">000421</idno>
<idno type="wicri:Area/Main/Curation">000421</idno>
<idno type="wicri:Area/Main/Exploration">000421</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Effect on efficacy and safety trial outcomes of also enrolling patients on ongoing glucocorticoid therapy in rheumatoid arthritis clinical trials of tocilizumab or adalimumab or methotrexate monotherapy.</title>
<author><name sortKey="Safy Khan, Mary" sort="Safy Khan, Mary" uniqKey="Safy Khan M" first="Mary" last="Safy-Khan">Mary Safy-Khan</name>
<affiliation wicri:level="3"><nlm:affiliation>Department of Rheumatology and Clinical Immunology, UMC Utrecht, Utrecht, The Netherlands marysafy@hotmail.com.</nlm:affiliation>
<country wicri:rule="url">Oman</country>
<wicri:regionArea>Department of Rheumatology and Clinical Immunology, UMC Utrecht, Utrecht</wicri:regionArea>
<placeName><settlement type="city">Utrecht</settlement>
<region nuts="2" type="province">Utrecht (province)</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Jacobs, Johannes W G" sort="Jacobs, Johannes W G" uniqKey="Jacobs J" first="Johannes W G" last="Jacobs">Johannes W G. Jacobs</name>
<affiliation wicri:level="3"><nlm:affiliation>Department of Rheumatology and Clinical Immunology, UMC Utrecht, Utrecht, The Netherlands.</nlm:affiliation>
<country xml:lang="fr">Pays-Bas</country>
<wicri:regionArea>Department of Rheumatology and Clinical Immunology, UMC Utrecht, Utrecht</wicri:regionArea>
<placeName><settlement type="city">Utrecht</settlement>
<region nuts="2" type="province">Utrecht (province)</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="De Hair, Maria J H" sort="De Hair, Maria J H" uniqKey="De Hair M" first="Maria J H" last="De Hair">Maria J H. De Hair</name>
<affiliation wicri:level="3"><nlm:affiliation>Novartis Pharma BV, Amsterdam, The Netherlands.</nlm:affiliation>
<country xml:lang="fr">Pays-Bas</country>
<wicri:regionArea>Novartis Pharma BV, Amsterdam</wicri:regionArea>
<placeName><settlement type="city">Amsterdam</settlement>
<region nuts="2" type="province">Hollande-Septentrionale</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Welsing, Paco M J" sort="Welsing, Paco M J" uniqKey="Welsing P" first="Paco M J" last="Welsing">Paco M J. Welsing</name>
<affiliation wicri:level="3"><nlm:affiliation>Department of Rheumatology and Clinical Immunology, UMC Utrecht, Utrecht, The Netherlands.</nlm:affiliation>
<country xml:lang="fr">Pays-Bas</country>
<wicri:regionArea>Department of Rheumatology and Clinical Immunology, UMC Utrecht, Utrecht</wicri:regionArea>
<placeName><settlement type="city">Utrecht</settlement>
<region nuts="2" type="province">Utrecht (province)</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Edwardes, Michael D" sort="Edwardes, Michael D" uniqKey="Edwardes M" first="Michael D" last="Edwardes">Michael D. Edwardes</name>
<affiliation wicri:level="1"><nlm:affiliation>Everest Clinical Research Canada, Markham, Ontario, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Everest Clinical Research Canada, Markham, Ontario</wicri:regionArea>
<wicri:noRegion>Ontario</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Teitsma, Xavier M" sort="Teitsma, Xavier M" uniqKey="Teitsma X" first="Xavier M" last="Teitsma">Xavier M. Teitsma</name>
<affiliation wicri:level="1"><nlm:affiliation>F Hoffmann-La Roche AG, Basel, Basel-Stadt, Switzerland.</nlm:affiliation>
<country xml:lang="fr">Suisse</country>
<wicri:regionArea>F Hoffmann-La Roche AG, Basel, Basel-Stadt</wicri:regionArea>
<wicri:noRegion>Basel-Stadt</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Luder, Yves" sort="Luder, Yves" uniqKey="Luder Y" first="Yves" last="Luder">Yves Luder</name>
</author>
<author><name sortKey="Devenport, Jenny" sort="Devenport, Jenny" uniqKey="Devenport J" first="Jenny" last="Devenport">Jenny Devenport</name>
<affiliation wicri:level="1"><nlm:affiliation>F Hoffmann-La Roche AG, Basel, Basel-Stadt, Switzerland.</nlm:affiliation>
<country xml:lang="fr">Suisse</country>
<wicri:regionArea>F Hoffmann-La Roche AG, Basel, Basel-Stadt</wicri:regionArea>
<wicri:noRegion>Basel-Stadt</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Van Laar, Jacob M" sort="Van Laar, Jacob M" uniqKey="Van Laar J" first="Jacob M" last="Van Laar">Jacob M. Van Laar</name>
<affiliation wicri:level="3"><nlm:affiliation>Department of Rheumatology and Clinical Immunology, UMC Utrecht, Utrecht, The Netherlands.</nlm:affiliation>
<country xml:lang="fr">Pays-Bas</country>
<wicri:regionArea>Department of Rheumatology and Clinical Immunology, UMC Utrecht, Utrecht</wicri:regionArea>
<placeName><settlement type="city">Utrecht</settlement>
<region nuts="2" type="province">Utrecht (province)</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Pethoe Schramm, Attila" sort="Pethoe Schramm, Attila" uniqKey="Pethoe Schramm A" first="Attila" last="Pethoe-Schramm">Attila Pethoe-Schramm</name>
<affiliation wicri:level="1"><nlm:affiliation>F Hoffmann-La Roche AG, Basel, Basel-Stadt, Switzerland.</nlm:affiliation>
<country xml:lang="fr">Suisse</country>
<wicri:regionArea>F Hoffmann-La Roche AG, Basel, Basel-Stadt</wicri:regionArea>
<wicri:noRegion>Basel-Stadt</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Bijlsma, Johannes W J" sort="Bijlsma, Johannes W J" uniqKey="Bijlsma J" first="Johannes W J" last="Bijlsma">Johannes W J. Bijlsma</name>
<affiliation wicri:level="3"><nlm:affiliation>Department of Rheumatology and Clinical Immunology, UMC Utrecht, Utrecht, The Netherlands.</nlm:affiliation>
<country xml:lang="fr">Pays-Bas</country>
<wicri:regionArea>Department of Rheumatology and Clinical Immunology, UMC Utrecht, Utrecht</wicri:regionArea>
<placeName><settlement type="city">Utrecht</settlement>
<region nuts="2" type="province">Utrecht (province)</region>
</placeName>
</affiliation>
</author>
</analytic>
<series><title level="j">Annals of the rheumatic diseases</title>
<idno type="eISSN">1468-2060</idno>
<imprint><date when="2020" type="published">2020</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass></textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">In rheumatoid arthritis (RA) trials, inclusion of patients on background treatment with glucocorticoids (GCs) might impact efficacy and safety outcomes.</div>
</front>
</TEI>
<affiliations><list><country><li>Canada</li>
<li>Oman</li>
<li>Pays-Bas</li>
<li>Suisse</li>
</country>
<region><li>Hollande-Septentrionale</li>
<li>Utrecht (province)</li>
</region>
<settlement><li>Amsterdam</li>
<li>Utrecht</li>
</settlement>
</list>
<tree><noCountry><name sortKey="Luder, Yves" sort="Luder, Yves" uniqKey="Luder Y" first="Yves" last="Luder">Yves Luder</name>
</noCountry>
<country name="Oman"><region name="Utrecht (province)"><name sortKey="Safy Khan, Mary" sort="Safy Khan, Mary" uniqKey="Safy Khan M" first="Mary" last="Safy-Khan">Mary Safy-Khan</name>
</region>
</country>
<country name="Pays-Bas"><region name="Utrecht (province)"><name sortKey="Jacobs, Johannes W G" sort="Jacobs, Johannes W G" uniqKey="Jacobs J" first="Johannes W G" last="Jacobs">Johannes W G. Jacobs</name>
</region>
<name sortKey="Bijlsma, Johannes W J" sort="Bijlsma, Johannes W J" uniqKey="Bijlsma J" first="Johannes W J" last="Bijlsma">Johannes W J. Bijlsma</name>
<name sortKey="De Hair, Maria J H" sort="De Hair, Maria J H" uniqKey="De Hair M" first="Maria J H" last="De Hair">Maria J H. De Hair</name>
<name sortKey="Van Laar, Jacob M" sort="Van Laar, Jacob M" uniqKey="Van Laar J" first="Jacob M" last="Van Laar">Jacob M. Van Laar</name>
<name sortKey="Welsing, Paco M J" sort="Welsing, Paco M J" uniqKey="Welsing P" first="Paco M J" last="Welsing">Paco M J. Welsing</name>
</country>
<country name="Canada"><noRegion><name sortKey="Edwardes, Michael D" sort="Edwardes, Michael D" uniqKey="Edwardes M" first="Michael D" last="Edwardes">Michael D. Edwardes</name>
</noRegion>
</country>
<country name="Suisse"><noRegion><name sortKey="Teitsma, Xavier M" sort="Teitsma, Xavier M" uniqKey="Teitsma X" first="Xavier M" last="Teitsma">Xavier M. Teitsma</name>
</noRegion>
<name sortKey="Devenport, Jenny" sort="Devenport, Jenny" uniqKey="Devenport J" first="Jenny" last="Devenport">Jenny Devenport</name>
<name sortKey="Pethoe Schramm, Attila" sort="Pethoe Schramm, Attila" uniqKey="Pethoe Schramm A" first="Attila" last="Pethoe-Schramm">Attila Pethoe-Schramm</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/TocilizumabV1/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000421 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000421 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    TocilizumabV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     pubmed:32033935
   |texte=   Effect on efficacy and safety trial outcomes of also enrolling patients on ongoing glucocorticoid therapy in rheumatoid arthritis clinical trials of tocilizumab or adalimumab or methotrexate monotherapy.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i   -Sk "pubmed:32033935" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd   \
       | NlmPubMed2Wicri -a TocilizumabV1

This area was generated with Dilib version V0.6.34.
Data generation: Fri May 22 09:34:00 2020. Site generation: Sun Mar 28 09:01:19 2021

Serveur d'exploration Tocilizumab

Effect on efficacy and safety trial outcomes of also enrolling patients on ongoing glucocorticoid therapy in rheumatoid arthritis clinical trials of tocilizumab or adalimumab or methotrexate monotherapy.

Effect on efficacy and safety trial outcomes of also enrolling patients on ongoing glucocorticoid therapy in rheumatoid arthritis clinical trials of tocilizumab or adalimumab or methotrexate monotherapy.

Source :

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki

	Serveur d'exploration Tocilizumab
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.